Share This Page
Drug Price Trends for MUCUS RELIEF D ER
✉ Email this page to a colleague
Average Pharmacy Cost for MUCUS RELIEF D ER
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MUCUS RELIEF D ER 600-60 MG TB | 70000-0580-01 | 0.30983 | EACH | 2025-04-23 |
| MUCUS RELIEF D ER 600-60 MG TB | 70000-0580-02 | 0.30983 | EACH | 2025-04-23 |
| MUCUS RELIEF D ER 600-60 MG TB | 70000-0580-01 | 0.32758 | EACH | 2025-03-19 |
| MUCUS RELIEF D ER 600-60 MG TB | 70000-0580-02 | 0.32758 | EACH | 2025-03-19 |
| MUCUS RELIEF D ER 600-60 MG TB | 70000-0580-02 | 0.34247 | EACH | 2025-02-19 |
| MUCUS RELIEF D ER 600-60 MG TB | 70000-0580-01 | 0.34247 | EACH | 2025-02-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for MUCUS RELIEF D ER
Introduction to MUCUS RELIEF D ER
MUCUS RELIEF D ER is a widely used over-the-counter (OTC) medication that combines guaifenesin and pseudoephedrine hydrochloride. This medication is designed to help loosen phlegm (mucus) and thin bronchial secretions, making coughs more productive and relieving nasal congestion due to common colds, hay fever, and upper respiratory allergies[4].
Market Overview of Expectorant Drugs
The market for expectorant drugs, which includes medications like MUCUS RELIEF D ER, is experiencing significant growth. The global expectorant drugs market was valued at US$ 16,384.6 million in 2023 and is projected to reach US$ 38,455.4 million by 2034, growing at a CAGR of 4.3% from 2024 to 2034. This growth is driven by increasing awareness of respiratory health, particularly in the wake of pandemics like COVID-19[3].
Guaifenesin Market Specifics
Guaifenesin, a key ingredient in MUCUS RELIEF D ER, is an expectorant that helps in cleaning phlegm and cough from the airways. The global guaifenesin market is forecasted to reach USD 95 million by 2027, growing at a CAGR of around 3.1% from 2022 to 2027. The cough treatment drug segment, which includes guaifenesin, is the fastest-growing segment, expected to grow with a CAGR of around 3.7% during the forecast period[1].
Price Projections for MUCUS RELIEF D ER
The current pricing for MUCUS RELIEF D ER varies based on the quantity and type of formulation. Here are some current price points:
- Extended Release Tablets: The cost for MUCUS RELIEF D ER (600 mg-60 mg) oral tablet, extended release, is around $11.08 for a supply of 18 tablets. This translates to approximately $0.62 per unit[2].
Given the market trends and the growing demand for expectorant drugs, prices are likely to remain stable or see a slight increase due to several factors:
- Demand and Supply: Increasing demand for respiratory medications, especially during flu seasons and pandemics, can lead to slight price increases.
- Manufacturing Costs: Any rise in the cost of raw materials or manufacturing processes could influence the final product price.
- Regulatory Factors: Changes in regulatory policies or healthcare reforms can impact the pricing of OTC medications.
However, the availability of generic versions and discount programs can help keep prices competitive. For example, the Drugs.com Discount Card can save consumers up to 80% or more off the cost of prescription and OTC drugs[2].
Segment Analysis by Application and End-Use Industry
By Application
The cough treatment drug segment, which includes MUCUS RELIEF D ER, is the fastest-growing segment. Guaifenesin is widely used in various forms such as syrups, tablets, and granules for both pediatric and geriatric populations. This broad application base is a significant driver for the market growth[1].
By End-Use Industry
Multispecialty hospitals hold the largest market share, with over 57% of the global guaifenesin market in 2021. The use of guaifenesin in hospitals for treating cough, chest congestion, bronchitis, and other respiratory issues is a major factor contributing to its demand[1].
Geographical Market Analysis
The demand for guaifenesin and subsequently MUCUS RELIEF D ER is distributed across various regions:
- North America: This region is a significant market due to the high prevalence of respiratory conditions and the well-established healthcare infrastructure.
- Europe: Countries like the UK, Germany, and France contribute substantially to the market.
- Asia-Pacific: The growing pharmaceutical sector in countries such as India, China, and Japan is driving the demand for guaifenesin-based medications[1].
Challenges and Opportunities
Challenges
The availability of substitutes and potential side effects are major challenges for the guaifenesin market. However, the specific formulation of MUCUS RELIEF D ER, combining guaifenesin with pseudoephedrine, offers a unique benefit that can mitigate some of these challenges[1].
Opportunities
Advancements in hospital infrastructure and innovations in drug delivery systems are expected to boost the growth prospects for guaifenesin. Additionally, government initiatives to improve respiratory health will further drive the demand for expectorant drugs like MUCUS RELIEF D ER[1].
Recent Developments
Recent approvals and launches in the guaifenesin market indicate a vibrant and evolving industry:
- Granules India: Received approval for guaifenesin extended-release tablets in February 2020.
- Aurobindo Pharma: Received approval from the USFDA for guaifenesin expectorant tablets in October 2019.
- Dr. Reddy's Laboratories: Launched an OTC store-brand equivalent of Mucinex D extended-release tablets in July 2019[1].
Key Takeaways
- The global guaifenesin market, including MUCUS RELIEF D ER, is expected to grow at a CAGR of around 3.1% from 2022 to 2027.
- The cough treatment drug segment is the fastest-growing segment, driven by the increasing application of guaifenesin in various forms.
- Multispecialty hospitals hold the largest market share, with a significant demand for guaifenesin-based medications.
- The market faces challenges from substitutes and side effects but is driven by advancements in healthcare infrastructure and government initiatives.
FAQs
What is MUCUS RELIEF D ER used for?
MUCUS RELIEF D ER is used to help loosen phlegm (mucus) and thin bronchial secretions, making coughs more productive and relieving nasal congestion due to common colds, hay fever, and upper respiratory allergies[4].
How much does MUCUS RELIEF D ER cost?
The cost for MUCUS RELIEF D ER (600 mg-60 mg) oral tablet, extended release, is around $11.08 for a supply of 18 tablets, which translates to approximately $0.62 per unit[2].
What are the potential side effects of MUCUS RELIEF D ER?
Potential side effects include nervousness, dizziness, sleeplessness, and symptoms that do not improve within 7 days or worsen with fever, rash, or persistent headache[4].
Are there any generic versions of MUCUS RELIEF D ER available?
Yes, generic versions of MUCUS RELIEF D ER are available, which can be more cost-effective for consumers[2].
What regions are driving the demand for guaifenesin-based medications?
The demand is driven by regions such as North America, Europe, and the Asia-Pacific, with significant contributions from countries like the USA, UK, Germany, India, and China[1].
Cited Sources
- IndustryARC: Guaifenesin Market Size Report, 2022-2027.
- Drugs.com: Mucus Relief D Prices, Coupons, Copay Cards & Patient Assistance.
- Future Market Insights: Global Expectorant Drugs Market Growth Projection 2024-2034.
- DailyMed: MUCUS RELIEF D- guaifenesin and pseudoephedrine hcl tablet, extended release.
More… ↓
